Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness

European Journal of Endocrinology

Volumn 166, Issue 5, 2012, Pages 847-854

  Ceolin, Lucieli ^a   Siqueira, Débora Rodrigues ^a   Ferreira, Carla Vaz ^a   Romitti, Mírian ^a   Maia, Silvana Cavalcante ^a   Leiria, Leonardo ^a   Crispim, Daisy ^a   Prolla, Patrícia Ashton ^a   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ADULT; ALLELE; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; RET GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID MEDULLARY CARCINOMA;

ADULT; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-RET; RISK FACTORS; THYROID NEOPLASMS;

EID: 84862110920     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1060     Document Type: Article

References (38)

1. Maia AL, Gross JL & Punales MK. Multiple endocrine neoplasia type 2. Arquivos Brasileiros de Endocrinologia e Metabologia 2005 49 725-734. (doi:10.1590/S0004-27302005000500013)
2. Marsh DJ, Learoyd DL & Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995 5 407-424. (doi:10.1089/thy.1995.5.407)
3. Pacini F, Castagna MG, Cipri C & Schlumberger M. Medullary thyroid carcinoma. Clinical Oncology 2010 22 475-485. (doi:10. 1016/j.clon.2010.05.002)
4. Eng C & Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Human Mutation 1997 9 97-109. (doi:10.1002/(SICI)1098- 1004(1997)9:2〈97::AIDHUMU1〉3.0.CO;2-M)
5. Punales MK, Graf H, Gross JL & Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. Journal of Clinical Endocrinology and Metabolism 2003 88 2644-2649. (doi:10.1210/jc.2002-021422)
6. Donis-Keller H. The RET proto-oncogene and cancer. Journal of Internal Medicine 1995 238 319-325. (doi:10.1111/j.1365-2796.1995.tb01205.x)
7. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C & Robinson BG. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clinical Endocrinology 1996 44 249-257. (doi:10.1046/j.1365-2265.1996.681503.x)
8. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN & Ponder BAJ. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics 1994 6 70-74. (doi:10.1038/ng0194-70)
9. Siqueira DR, Romitti M, da Rocha AP, Ceolin L, Meotti C, Estivalet A, Punales MK & Maia AL. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocrine- Related Cancer 2010 17 953-963. (doi:10.1677/ERC-09-0312)
10. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA & Ponder BA. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Research 1996 56 2167-2170. (Pubitemid 26119920)
11. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G & Pacini F. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Journal of Clinical Endocrinology and Metabolism 1996 81 1619-1622. (doi:10.1210/jc.81.4.1619)
12. Ceolin L, Siqueira DR, Romitti M, Ferreira CV & Maia AL. Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. International Journal of Molecular Sciences 2012 13 221-239. (doi:10.3390/ijms13010221)
13. Landa I & Robledo M. Association studies in thyroid cancer susceptibility: are we on the right track? Journal of Molecular Endocrinology 2011 47 R43-R58. (doi:10.1530/JME-11-0005)
14. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F & Pinchera A. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. Journal of Clinical Endocrinology and Metabolism 2004 89 3579-3584. (doi:10.1210/jc.2003-031898)
15. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM & Ponder BA. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2005 90 6268-6274. (doi:10.1210/jc.2004-2449)
16. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z & Jarzab B. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. Journal of Clinical Oncology 2001 19 1374-1380. (Pubitemid 32202543)
17. Sromek M, Czetwertynska M, Skasko E, Zielinska J, Czapczak D & Steffen J. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland. Endocrine Pathology 2010 21 178-185. (doi:10.1007/s12022-010- 9125-8)
18. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I & Borrego S. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clinical Endocrinology 2001 55 399-402. (doi:10.1046/j.1365-2265. 2001.01328.x)
19. Berard I, Kraimps JL, Savagner F, Murat A, Renaudin K, Nicolli- Sire P, Bertrand G, Moisan JP & Bezieau S. Germline-sequence variants S836S and L769L in the RE arranged during transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clinical Genetics 2004 65 150-152. (doi:10.1111/j.0009-9163.2004. 00172.x)
20. Gursoy A, ErdoganMF & Erdogan G. Significance of the RET protooncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients. Journal of Endocrinological Investigation 2006 29 858-862. (Pubitemid 46165008)
21. Wohllk N, Soto E, Bravo M & Becker P. Polimorfismos G691S, L769L y S836S del proto-oncogen RET no se asocian a mayor riesgo de cáncer medular tiroideo esporádico en pacientes chilenos. Revista Médica de Chile 2005 133 397-402.
22. Tamanaha R, Camacho CP, Pereira AC, da Silva AM, Maciel RM & Cerutti JM. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. Clinical Endocrinology 2009 71 56-64. (doi:10.1111/j.1365-2265. 2008.03491.x)
23. Baumgartner-Parzer SM, Lang R,Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W & Vierhapper H. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism 2005 90 6232-6236. (doi:10.1210/jc.2005- 1278)
24. Beuten J, Gelfond JA, Franke JL,Weldon KS, Crandall AC, Johnson- Pais TL, Thompson IM & Leach RJ. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2009 18 1869-1880. (doi:10.1158/1055-9965.EPI-09-0076)
25. Schottenfeld D. Genetic and environmental factors in human carcinogenesis. Journal of Chronic Diseases 1986 39 1021-1030. (doi:10.1016/0021-9681(86)90137-2)
26. Punales MK, da Rocha AP, Meotti C, Gross JL & Maia AL. Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A. Thyroid 2008 18 1261-1268. (doi:10.1089/thy.2007.0414)
27. Stephens M, Smith NJ & Donnelly P. A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics 2001 68 978-989. (doi:10.1086/319501)
28. Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics 1987 117 331-341.
29. Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J & Rojas JM. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Research 2003 63 1814-1817. (Pubitemid 36460842)
30. Fernandez RM, Pecina A, Antinolo G, Navarro E & Borrego S. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma. Thyroid 2006 16 411-417. (doi:10.1089/thy.2006.16.411)
31. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H & Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999 18 1369-1373. (doi:10.1038/sj.onc.1202418)
32. Song M, Lee KM & Kang D. Breast cancer prevention based on gene-environment interaction. Molecular Carcinogenesis 2011 50 280-290. (doi:10.1002/mc.20639)
33. Lesueur F, Corbex M, McKay JD, Lima J, Soares P, Griseri P, Burgess J, Ceccherini I, Landolfi S, Papotti M, Amorim A, Goldgar DE & Romeo G. Specific haplotypes of the RET protooncogene are over-represented in patients with sporadic papillary thyroid carcinoma. Journal of Medical Genetics 2002 39 260-265. (doi:10.1136/jmg.39.4.260)
34. Phillips CM, Goumidi L, Bertrais S, Ferguson JF, Field MR, Kelly ED, Mehegan J, Peloso GM, Cupples LA, Shen J, Ordovas JM, McManus R, Hercberg S, Portugal H, Lairon D, Planells R & Roche HM. Additive effect of polymorphisms in the IL-6, LTA, and TNF-{alpha} genes and plasma fatty acid level modulate risk for the metabolic syndrome and its components. Journal of Clinical Endocrinology and Metabolism 2010 95 1386-1394. (doi:10.1210/jc.2009- 1081)
35. Miyajima F, Quinn JP, Horan M, Pickles A, Ollier WE, Pendleton N & Payton A. Additive effect of BDNF and REST polymorphisms is associated with improved general cognitive ability. Genes, Brain and Behavior 2008 7 714-719. (doi:10.1111/j.1601-183X.2008.00409.x)
36. Sfar S, Saad H, Mosbah F & Chouchane L. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Molecular Biology Reports 2009 36 37-45. (doi:10.1007/s11033- 007-9149-4)
37. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G & Eng C. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. Journal of Medical Genetics 1999 36 771-774. (Pubitemid 29462322)
38. Griseri P, Sancandi M, Patrone G, Bocciardi R, Hofstra R, Ravazzolo R, Devoto M, Romeo G & Ceccherini I. A singlenucleotide polymorphic variant of the RET proto-oncogene is underrepresented in sporadic Hirschsprung disease. European Journal of Human Genetics 2000 8 721-724. (doi:10.1038/sj.ejhg.5200521)